Aptar Pharma launches inhaled biologics research pact with Macquarie University

Aptar Pharma has started a three-year research collaboration with Macquarie University in Sydney to study delivery of high-dose dry powder biologic therapies. The project, backed by an Australian Research Council Linkage Project grant, will use Aptar's Orbital dry powder inhaler platform to test how formulation choices affect aerosol performance for large biologic molecules.

Why this mattersAcademic validation of the Orbital platform for large-molecule biologics could support Aptar's push into pulmonary delivery as drugmakers seek alternatives to injectables.

• Three-year programme titled Unlocking the Potential of Dry Powder Carriers for Biologic Applications, ARC grant reference LP250100089
• Funded jointly by the Australian Research Council Linkage Project scheme and industry partners
• Research uses Aptar Pharma's Orbital dry powder inhaler platform for high-payload dry powder formulations
• Study will examine how formulation variables affect aerosol performance on the Orbital platform

Relevant to you? Yes No